TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer [Yahoo! Finance]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Yahoo! Finance
company leveraging its global presence and core non-viral platform to advance and democratize CAR-T therapy for patients worldwide, today announced the appointment of Douglas E. Williams, Ph.D. as Chief Executive Officer (CEO). “Doug is an accomplished biopharmaceutical veteran with over 30 years of cross-functional drug development expertise, senior corporate leadership experience, proven capital markets prowess and strategic deal-making savvy, as well as a strong track record of delivering paradigm-shifting products to patients, including several blockbusters such as Enbrel®, Tecfidera®, and Spinraza®,” said James Huang, Founder and Executive Chairman of the Board of Directors of TriArm. “We are beyond delighted to welcome Doug as CEO to lead TriArm through our next phase of growth and have him at the helm as we carry out our mission of advancing safer, more effective, and lower-cost CAR-T products for patients around the world.” “TriArm is an emerging force in the development o
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Sana Biotechnology to Present at September 2024 Investor ConferencesGlobeNewswire
- Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific OfficerGlobeNewswire
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target raised by analysts at Citigroup Inc. from $8.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
SANA
Earnings
- 8/8/24 - Miss
SANA
Sec Filings
- 9/12/24 - Form 8-K
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- SANA's page on the SEC website